- Home
- CRBP
as 07-26-2024 4:00pm EST
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NORWOOD |
| Market Cap: | 471.6M | IPO Year: | N/A |
| Target Price: | $74.60 | AVG Volume (30 days): | 344.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.03 - $61.18 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Corbus Pharmaceuticals Holdings Inc. (CRBP)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moran Sean F. | CRBP | Chief Financial Officer | Jun 14 '24 | Sell | $42.12 | 1,958 | $82,479.18 | 48,605 | SEC Form 4 |
| Moran Sean F. | CRBP | Chief Financial Officer | Jun 14 '24 | Sell | $46.77 | 6,730 | $314,789.02 | 48,605 | SEC Form 4 |
| Moran Sean F. | CRBP | Chief Financial Officer | Jun 14 '24 | Sell | $49.87 | 7,788 | $388,417.15 | 48,605 | SEC Form 4 |
| Moran Sean F. | CRBP | Chief Financial Officer | Jun 14 '24 | Sell | $49.87 | 1,567 | $78,152.24 | 48,605 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Mar 7 '24 | Buy | $37.82 | 46,799 | $1,769,938.18 | 1,521,799 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Mar 7 '24 | Buy | $39.13 | 10,736 | $420,099.68 | 1,532,535 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Mar 7 '24 | Buy | $39.99 | 90,325 | $3,612,096.75 | 1,622,860 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Mar 7 '24 | Buy | $41.23 | 102,140 | $4,211,232.20 | 1,725,000 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Mar 7 '24 | Buy | $41.23 | 29,342 | $1,209,770.66 | 1,754,342 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Mar 7 '24 | Buy | $42.25 | 24,983 | $1,055,531.75 | 1,779,325 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Mar 7 '24 | Buy | $43.26 | 18,548 | $802,386.48 | 1,797,873 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Mar 7 '24 | Buy | $44.62 | 61,668 | $2,751,626.16 | 1,859,541 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Mar 7 '24 | Buy | $45.26 | 156,597 | $7,087,580.22 | 2,016,138 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Mar 7 '24 | Buy | $45.96 | 8,862 | $407,297.52 | 2,025,000 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Feb 2 '24 | Buy | $19.00 | 750,000 | $14,250,000.00 | 1,475,000 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Jan 26 '24 | Buy | $25.73 | 14,388 | $370,203.24 | 456,756 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Jan 26 '24 | Buy | $26.66 | 15,243 | $406,378.38 | 471,999 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Jan 26 '24 | Buy | $27.70 | 36,747 | $1,017,891.90 | 508,746 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Jan 26 '24 | Buy | $28.82 | 31,028 | $894,226.96 | 539,774 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Jan 26 '24 | Buy | $29.42 | 29,244 | $860,358.48 | 569,018 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Jan 26 '24 | Buy | $31.00 | 2,654 | $82,274.00 | 571,672 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Jan 26 '24 | Buy | $31.86 | 4,125 | $131,422.50 | 575,797 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Jan 26 '24 | Buy | $32.47 | 3,866 | $125,529.02 | 579,663 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Jan 26 '24 | Buy | $33.71 | 18,055 | $608,634.05 | 597,718 | SEC Form 4 |
| Cormorant Asset Management, LP | CRBP | 10% Owner | Jan 26 '24 | Buy | $34.62 | 31,549 | $1,092,226.38 | 629,267 | SEC Form 4 |
Latest Corbus Pharmaceuticals Holdings Inc. News
CRBP Breaking Stock News: Dive into CRBP Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
GlobeNewswire
2 months ago
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
GlobeNewswire
2 months ago
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
GlobeNewswire
3 months ago
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Associated Press Finance
3 months ago
Corbus Pharmaceuticals: Q1 Earnings Snapshot
GlobeNewswire
3 months ago
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
3 months ago
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
GlobeNewswire
3 months ago
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
Compare CRBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRBP Corbus Pharmaceuticals Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.